A number of other research firms also recently weighed in on HZNP. BidaskClub upgraded Horizon Pharma from a hold rating to a buy rating in a report on Friday, December 22nd. ValuEngine downgraded Horizon Pharma from a buy rating to a hold rating in a report on Sunday, December 31st. Jefferies Group increased their price objective on Horizon Pharma from $16.00 to $21.00 and gave the company a buy rating in a report on Tuesday, November 7th. Stifel Nicolaus restated a buy rating and issued a $20.00 price objective on shares of Horizon Pharma in a report on Sunday, October 22nd. Finally, Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma and gave the company a buy rating in a report on Sunday, October 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. Horizon Pharma presently has an average rating of Buy and an average price target of $19.25.
Horizon Pharma (NASDAQ:HZNP) traded down $0.07 during midday trading on Monday, reaching $15.09. The company had a trading volume of 2,381,000 shares, compared to its average volume of 1,648,137. The firm has a market capitalization of $2,400.00, a P/E ratio of -4.96, a price-to-earnings-growth ratio of 0.73 and a beta of 1.30. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $17.69. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. Horizon Pharma’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. sell-side analysts anticipate that Horizon Pharma will post 0.72 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Advantage Investment Management LLC raised its holdings in shares of Horizon Pharma by 164.8% during the third quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,900 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Horizon Pharma by 16.3% during the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares during the last quarter. Sheaff Brock Investment Advisors LLC raised its holdings in shares of Horizon Pharma by 5.0% during the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 500 shares during the last quarter. Family Management Corp purchased a new position in shares of Horizon Pharma during the second quarter valued at approximately $131,000. Finally, Brown Advisory Inc. purchased a new position in shares of Horizon Pharma during the third quarter valued at approximately $145,000. 86.58% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://ledgergazette.com/2018/01/12/horizon-pharma-hznp-given-a-17-00-price-target-by-cantor-fitzgerald-analysts.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.